



NeoVista®, Inc. Reports VIDION® ANV® Therapy System Utilization in Mainz, Germany, for the Treatment of Neovascular Age-Related Macular Degeneration

Eye Clinic of the Medical University Johannes Gutenberg in Mainz performs Epimacular Brachytherapy outside of a clinical study.

Newark, CA ([PRWEB](#)) July 21, 2011 -- NeoVista, Inc. announced today an expansion of the commercial acceptance of Epimacular Brachytherapy in Mainz, Germany. Epimacular Brachytherapy (EMBT) is now available for the treatment of neovascular (wet) age-related macular degeneration (AMD). Utilizing the VIDION ANV Therapy system, EMBT is being offered as an adjunct therapy to anti-VEGF injections.

Dr. Bernhard M. Stoffelns, FEBO, Head of the Retina Unit at the Eye Clinic of the Johannes Gutenberg Medical University in Mainz, stated: "After beginning treatment with the first patient on 8/6/2011, we conducted 7 treatments so far (about 1-2 per week). After returning from my summer holidays in August / September, 5 more treatments have already firmly scheduled. We did not see any problems during the treatments so far. All operations were performed under local anesthesia and all, except for one previously pseudophakic eye - with combined cataract surgery. We performed a transconjunctival 25 gauge vitrectomy and enlarged one sclerotomy to 20 gauge for the brachytherapy hand piece. The combined cataract surgery was standardized with no-stitch trans-corneal tunnel technique and foldable IOL implantation. All patients were relieved after surgery and reported that they experienced the surgery to be much less stressful than they would have expected. "

John N. Hendrick, President and CEO of NeoVista commented, "We are pleased to learn of the positive feedback from the Johannes Gutenberg Medical University. Our purposeful approach to market entry has permitted our own field personnel and our business partners in each country to work closely with all of the early adopters of EMBT through-out the world. As such, we have been able to gain greater insight into the benefits of our procedure for the multitude of patients who suffer from this debilitating and life-altering disease. This is especially important as we continue the introduction of EMBT in to other markets. The burden of wet AMD to those afflicted with the disease, and their caregivers, is enormous to every healthcare system."

Mr. Hendrick added, "We continue to receive confirmation from the market that our novel treatment approach to treating wet AMD greatly reduces the number of anti-VEGF injections, while maintaining visual acuity – especially in those lesion subtypes that typically require a large number of injections."

Epimacular Brachytherapy delivers a focused dose of strontium 90 beta radiation directly to the back of the eye (retina), without damaging the adjacent healthy retinal vasculature. Importantly for patients, the one-time exposure to radiation is very low; the dose delivered to the entire body from this one-time treatment is less than that from a typical chest x-ray. EMBT allows for energy to be delivered in a highly controlled manner to a focused area of tissue.

About NeoVista, Inc.

NeoVista, Inc. is a privately held medical device company based in Newark, California. For more information about the company, or this novel therapy, please visit the company's Web site at www.neovistainc.com.

###



Contact Information

Tony Moses

NeoVista, Inc.

(510) 402-3394

Online Web 2.0 Version

You can read the online version of this press release [here](#).